2. Search Result
Search Result
Results for "

cardiac injury

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

4

Peptides

6

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111475
    Mitochondrial fusion promoter M1
    1 Publications Verification

    		 Mitochondrial Metabolism Cardiovascular Disease
    Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury .
    Mitochondrial fusion promoter M1
  • HY-B1203A
    Fludrocortisone acetate
    1 Publications Verification

    9α-Fludrocortisone acetate; 9α-Fluorcortisol acetate

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Fludrocortisone acetate (9α-Fludrocortisone acetate) is an orally active synthetic mineralocorticoid. Fludrocortisone acetate can effectively control sodium retention. Fludrocortisone acetate is used in studies of cardiac injury, adrenal insufficiency and orthostatic hypotension .
    Fludrocortisone acetate
  • HY-134259
    MEISi-2

    		HOXA Cancer
    MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .
    MEISi-2
  • HY-117243
    GSK329

    		MAP3K Cardiovascular Disease
    GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury .
    GSK329
  • HY-W015061
    Phenylacetylglycine
    1 Publications Verification

    		 Adrenergic Receptor Apoptosis Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion .
    Phenylacetylglycine
  • HY-161834
    RG100204

    		Aquaporin Infection Inflammation/Immunology
    RG100204 is an orally active AQP9 inhibitor with anti-inflammatory activity. RG100204 can alleviate sepsis-induced cardiac dysfunction (both systolic and diastolic), improve renal dysfunction, and reduce the elevation of LDH, a marker of cellular injury .
    RG100204
  • HY-130272
    Anti-MI/R injury agent 1

    		Others Cardiovascular Disease
    Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .
    Anti-MI/R injury agent 1
  • HY-13315S1
    Montelukast-d6 sodium

    MK0476-d6

    		 Leukotriene Receptor Inflammation/Immunology
    Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
    Montelukast-d6 sodium
  • HY-13315S
    Montelukast-d6

    MK0476-d6 free acid

    		 Isotope-Labeled Compounds Leukotriene Receptor Inflammation/Immunology
    Montelukast-d6 is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
    Montelukast-d6
  • HY-W015061R
    Phenylacetylglycine (Standard)

    		Adrenergic Receptor Apoptosis Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Phenylacetylglycine (Standard) is the analytical standard of Phenylacetylglycine. This product is intended for research and analytical applications. Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion .
    Phenylacetylglycine (Standard)
  • HY-W015061S
    N-(Phenylacetyl-d5)glycine

    2-(2-Phenylacetamido)acetic acid-d5

    		 Adrenergic Receptor Apoptosis Endogenous Metabolite Cardiovascular Disease
    N-(Phenylacetyl-d5)glycine is the deuterium labeled Phenylacetylglycine. Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion[1][2].
    N-(Phenylacetyl-d5)glycine
  • HY-P1235A
    Carperitide acetate
    3 Publications Verification

    Atrial Natriuretic Peptide (ANP) (1-28), human, porcine acetate

    		 Endothelin Receptor Cardiovascular Disease Endocrinology
    Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine acetate) is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. Carperitide acetate inhibits endothelin-1 secretion in a dose-dependent way.
    Carperitide acetate
  • HY-P3199
    PKCβII Peptide Inhibitor I

    		PKC Inflammation/Immunology
    PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .
    PKCβII Peptide Inhibitor I
  • HY-13315
    Montelukast sodium
    5+ Cited Publications

    MK0476

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
    Montelukast sodium
  • HY-13315A
    Montelukast
    5+ Cited Publications

    MK0476 free base

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
    Montelukast
  • HY-13315B
    Montelukast dicyclohexylamine

    MK0476 dicyclohexylamine

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
    Montelukast dicyclohexylamine
  • HY-13315R
    Montelukast (sodium) (Standard)

    MK0476 (Standard)

    		 Leukotriene Receptor Inflammation/Immunology
    Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
    Montelukast (sodium) (Standard)
  • HY-P1235
    Carperitide

    Atrial Natriuretic Peptide (ANP) (1-28), human, porcine

    		 Endothelin Receptor Cardiovascular Disease Endocrinology
    Carperitide (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine) is a 28-amino acid hormone, that is normally produced and secreted by the human heart in response to cardiac injury and mechanical stretch. Carperitide (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine) inhibits endothelin-1 secretion in a dose-dependent way.
    Carperitide
  • HY-13315AR
    Montelukast (Standard)

    		Leukotriene Receptor Inflammation/Immunology
    Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
    Montelukast (Standard)
  • HY-134263
    8-Br-cAMP-AM

    		PKA Ras Cardiovascular Disease
    8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .
    8-Br-cAMP-AM
  • HY-13315BR
    Montelukast (dicyclohexylamine) (Standard)

    		Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (dicyclohexylamine) (Standard) is the analytical standard of Montelukast (dicyclohexylamine). This product is intended for research and analytical applications. Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
    Montelukast (dicyclohexylamine) (Standard)
  • HY-137629
    Sp-8-pCPT-PET-cGMPS

    		PKG Cardiovascular Disease
    Sp-8-pCPT-PET-cGMPS is an activator for PKG-I. Sp-8-pCPT-PET-cGMPS can be used for research of NO/NOS/sGC/PKG-I signaling pathway in cardiac differentiation .
    Sp-8-pCPT-PET-cGMPS
  • HY-16121
    CAA-0225

    		Cathepsin Others
    CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC50 value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites [1][2][3].
    CAA-0225
  • HY-169052
    Cyy-272

    		JNK Apoptosis Cardiovascular Disease Inflammation/Immunology
    Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy .
    Cyy-272
  • HY-116171
    (Rac)-Calpain Inhibitor XII

    		Proteasome Cardiovascular Disease Neurological Disease
    (Rac)-Calpain Inhibitor XII is a reversible and selective inhibitor of calpain I (μ-calpain, Ki=19 nM). (Rac)-Calpain Inhibitor XII has lower affinities for calpain II (m-calpain, Ki=120 nM) and cathepsin B (Ki=750 nM). (Rac)-Calpain Inhibitor XII has the potential for studying the role of calpains in diverse processes, including neutrophil chemotaxis, neuronal signaling, and cardiac response to injury .
    (Rac)-Calpain Inhibitor XII
  • HY-N6605
    Kaempferol 3-O-β-D-galactopyranoside
    1 Publications Verification

    Trifolin

    		 Apoptosis Cardiovascular Disease Cancer
    Kaempferol 3-O-β-D-galactopyranoside (Trifolin) is an orally active flavonoid derivative that can be found in the aerial parts of Consolida oliverana. Kaempferol 3-O-β-D-galactopyranoside exhibits antitumor and cardioprotective effects .
    Kaempferol 3-O-β-D-galactopyranoside
  • HY-A0113
    Cilazaprilat

    Ro 31-3113

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.
    Cilazaprilat
  • HY-P5762A
    Phoenixin-14 TFA

    PNX-14 TFA

    		 GnRH Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Phoenixin-14 (PNX-14) TFA, a neuropeptide, has anxiolytic, cardioprotective and neuroprotective effect. Phoenixin-14 TFA can regulate pituitary gonadotrophin secretion by upregulating the GnRH receptor mRNA. Phoenixin-14 TFA stimulates insulin secretion. Phoenixin-14 TFA also protects mice from ischemia/reperfusion (IR) injury. PNX-14 TFA prevents oxidative stress by reducing ROS and increasing GSH .
    Phoenixin-14 TFA
  • HY-Y1787
    Dimethyl malonate
    2 Publications Verification

    		 Apoptosis Neurological Disease
    Dimethyl malonate is a competitive inhibitor of succinate dehydrogenase (SDH). Dimethyl malonate is able to cross the blood-brain barrier and hydrolyse to malonate. Dimethyl malonate reduces neuronal apoptosis .
    Dimethyl malonate
  • HY-155517
    INF200

    		NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation .
    INF200
  • HY-119038
    ML-7

    		Endogenous Metabolite Cardiovascular Disease
    ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury .
    ML-7
  • HY-N1441
    Afzelin
    4 Publications Verification

    Kaempferol-3-O-rhamnoside

    		 Mitochondrial Metabolism PTEN Autophagy Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin .
    Afzelin
  • HY-W017540
    Cyclocreatine
    1 Publications Verification

    		 ATP Synthase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
    Cyclocreatine
  • HY-N1441R
    Afzelin (Standard)

    		Mitochondrial Metabolism PTEN Autophagy Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Afzelin (Standard) is the analytical standard of Afzelin. This product is intended for research and analytical applications. Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin .
    Afzelin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: